Decheng Capital’s ACELYRIN SLRN Stock Holding History

Decheng Capital’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,370,951	Closed	-$10.2M	–	28
2023 Q4	$10.2M	Buy	+1,370,951	New	+$11.7M	2.86%	11

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Decheng Capital's SLRN Position: Q1 2024 in Review

Decheng Capital sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 1,370,951 shares — an estimated $10.2M sold.

Decheng Capital first reported a position in SLRN in Q4 2023 and held it in 1 quarter. The position peaked at $10.2M in Q4 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

Decheng Capital reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
Decheng Capital sold 1,370,951 ACELYRIN shares in Q1 2024, an estimated $10.2M.
Decheng Capital first reported a position in ACELYRIN in Q4 2023 and held it in 1 quarter.
Decheng Capital's ACELYRIN position peaked at $10.2M in Q4 2023.
109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Decheng Capital's 13F filing for Q1 2024, filed 14 May 2024.